ArticleFrontiers in medicine2024
Malignant breast adenomyoepithelioma: case report and literature review.
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Malignant breast adenomyoepithelioma with diagnostic discordance: a case report and literature review.Frontiers in oncology · 2026Article
- Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?OncoTargets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant adenomyoepithelioma (MAME) of the breast is a rare tumor with both benign and malignant features. We report a case of a 67-year-old woman who presented with a mass in the outer quadrant of the right breast, detected during a routine check-up. The mass was classified as BI-RADS 3. After minimally invasive excision, pathology confirmed low-grade malignant adenomyoepithelioma. The patient then underwent total mastectomy and sentinel lymph node biopsy (SLNB). At two years of follow-up, there was no recurrence or metastasis. This case highlights the rarity of MAME and the importance of early diagnosis and complete excision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.